HF
IRD

HRT Financial’s Opus Genetics IRD Stock Holding History

HRT Financial’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
+67,663
New +$234K ﹤0.01% 2858
2025
Q4 		– Sell
-20,677
Closed -$34K – 4257
2025
Q3 		$34K Buy
+20,677
New +$25.7K ﹤0.01% 2644
2025
Q2 		– Sell
-15,168
Closed -$14K – 3733
2025
Q1 		$14K Buy
+15,168
New +$16.9K ﹤0.01% 2332
2024
Q2 		– Sell
-19,868
Closed -$39K – 3278
2024
Q1 		$39K Buy
+19,868
New +$50.4K ﹤0.01% 1957

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HRT Financial's IRD Position: Q1 2026 in Review

HRT Financial opened a new position in Opus Genetics (IRD) in Q1 2026: 67,663 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #2858 among its holdings. This is a return to the name: HRT Financial previously reported a position in IRD as recently as Q3 2025.

HRT Financial first reported a position in IRD in Q1 2024 and has held it in 4 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • HRT Financial held 67,663 shares of Opus Genetics worth $307K as of Q1 2026.
  • Opus Genetics was a new HRT Financial position in Q1 2026.
  • Opus Genetics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2858 holding.
  • HRT Financial first reported a position in Opus Genetics in Q1 2024 and has held it in 4 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.